[Osteoporotic fracture in menopausal women: alendronate reduces the risk].
Bize
R
R
Institut universitaire de médecine sociale et préventive de l'Université de Lausanne et Réseau francophone Cochrane Bugnon 17, 1005 Lausanne.
Lamy
O
O
Peytremann-Bridevaux
I
I
D019386:Alendronate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006620:Hip Fractures / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D011322:Primary Prevention; D012307:Risk Factors; D055502:Secondary Prevention; D016103:Spinal Fractures / Q000517:prevention & control
D050071:Bone Density Conservation Agents; D019386:Alendronate